

Appointment of Corporate Advisor

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today advises that it has appointed Merchant Corporate Advisory Australia Pty Ltd ("**Merchant**") as its corporate adviser under a corporate advisory mandate ("**Mandate**").

Under the terms of this Mandate, Merchant will provide corporate advisory services to the Company (including investor introduction and market communication services). Subject to shareholder and ASX approval and as consideration for these services, Neurotech will issue 25,000,000 options to Merchant (or its nominees) in lieu of cash fees ("**Options**").

The Options will be exercisable from issue at \$0.06 per option ("**Exercise Price**") and will expire 12 months from the date of execution of the Mandate ("**Expiry Date**"). Each Option will have a piggy back right whereby if it is exercised within 6 months (from the date of signing the Mandate), a further option will be issued to Merchant (or its nominees) with the same Exercise Price and Expiry Date as the Options.

The issue, and terms, of these Options are subject to shareholder approval being obtained at the 2023 Annual General Meeting or a future General Meeting. If shareholder approval for the issue of the Options is not obtained, the Mandate will be deemed to be terminated with no further fee or cash payable from Neurotech to Merchant. If the issue of these options is not approved by ASX, the Company and Merchant will negotiate in good faith a quantity and term of options that are acceptable.

In the event that no agreement can be made between the two parties then the mandate will be deemed to be terminated and no fee will be payable, cash or otherwise.

The Mandate may be terminated by either party, with or without cause, at any time, by providing one month's notice to the other party. The other terms of this Mandate are standard for an agreement of this nature.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Investors/Media:

Dr Thomas Duthy
Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune

Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.